USP7 Enables Immune Escape of Glioma Cells by Regulating PD-L1 Expression

References

• Akutsu M, Dikic I, Bremm A. 2016. Ubiquitin chain diversity at a glance. J Cell Sci. 129(5):875–80.
   PubMed Web of Science ®Google Scholar
• Antao AM, Tyagi A, Kim KS, Ramakrishna S. 2020. Advances in deubiquitinating enzyme inhibition and applications in cancer therapeutics. Cancers (Basel). 12(6):1579.
   PubMed Web of Science ®Google Scholar
• Barsoum IB, Koti M, Siemens DR, Graham CH. 2014. Mechanisms of hypoxia-mediated immune escape in cancer. Cancer Res. 74(24):7185–90.
   PubMed Web of Science ®Google Scholar
• Bie F, Tian H, Sun N, Zang R, Zhang M, Song P, Liu L, Peng Y, Bai G, Zhou B, et al. 2022. Research progress of Anti-PD-1/PD-L1 immunotherapy related mechanisms and predictive biomarkers in NSCLC. Front Oncol. 12:769124.
   PubMedGoogle Scholar
• Chen Y, Xu J, Wu X, Yao H, Yan Z, Guo T, Wang W, Wang P, Li Y, Yang X, et al. 2021. CD147 regulates antitumor CD8(+) T-cell responses to facilitate tumor-immune escape. Cell Mol Immunol. 18(8):1995–2009.
   PubMed Web of Science ®Google Scholar
• Cheng C, Niu C, Yang Y, Wang Y, Lu M. 2013. Expression of HAUSP in gliomas correlates with disease progression and survival of patients. Oncol Rep. 29(5):1730–36.
   PubMedGoogle Scholar
• Dai X, Lu L, Deng S, Meng J, Wan C, Huang J, Sun Y, Hu Y, Wu B, Wu G, et al. 2020. USP7 targeting modulates anti-tumor immune response by reprogramming Tumor-associated Macrophages in Lung Cancer. Theranostics. 10(20):9332–47.
   PubMed Web of Science ®Google Scholar
• Danilovskyi SV, Minchenko DO, Moliavko OS, et al. 2014. ERN1 knockdown modifies the hypoxic regulation of TP53, MDM2, USP7 and PERP gene expressions in U87 glioma cells. Ukr Biochem J. 86(4):90–102.
   PubMedGoogle Scholar
• De Jaeghere EA, Denys HG, De Wever O. 2019. Fibroblasts fuel immune escape in the tumor microenvironment. Trends Cancer. 5(11):704–23.
   PubMedGoogle Scholar
• Du L, Lee JH, Jiang H, Wang C, Wang S, Zheng Z, Shao F, Xu D, Xia Y, Li J, et al. 2020. β-Catenin induces transcriptional expression of PD-L1 to promote glioblastoma immune evasion. J Exp Med. 217(11). doi:10.1084/jem.20191115.
   Web of Science ®Google Scholar
• Farhood B, Najafi M, Mortezaee K. 2019. CD8(+) cytotoxic T lymphocytes in cancer immunotherapy: a review. J Cell Physiol. 234(6):8509–21.
   PubMed Web of Science ®Google Scholar
• Fu C, Zhu X, Xu P, Li Y. 2019. Pharmacological inhibition of USP7 promotes antitumor immunity and contributes to colon cancer therapy. onco Targets Ther. 12:609–17.
   PubMed Web of Science ®Google Scholar
• Harakandi C, Nininahazwe L, Xu H, Liu B, He C, Zheng Y-C, Zhang H. 2021. Recent advances on the intervention sites targeting USP7-MDM2-p53 in cancer therapy. Bioorg Chem. 116:105273.
   PubMedGoogle Scholar
• Leestemaker Y, Ovaa H. 2017. Tools to investigate the ubiquitin proteasome system. Drug Discov Today Technol. 26:25–31.
   PubMedGoogle Scholar
• Li P, Huang T, Zou Q, Liu D, Wang Y, Tan X, Wei Y, Qiu H. 2019. FGFR2 promotes expression of PD-L1 in colorectal cancer via the JAK/STAT3 signaling pathway. J Immunol. 202(10):3065–75.
   PubMed Web of Science ®Google Scholar
• Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, Su X, Wang Y, Gonzalez-Angulo AM, Akcakanat A, et al. 2014. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res. 2(4):361–70.
   PubMed Web of Science ®Google Scholar
• Morrow JK, Lin HK, Sun SC, Zhang S. 2015. Targeting ubiquitination for cancer therapies. Future Med Chem. 7(17):2333–50.
   PubMed Web of Science ®Google Scholar
• Ostrom QT, Gittleman H, Farah P, Ondracek A, Chen Y, Wolinsky Y, Stroup NE, Kruchko C, Barnholtz-Sloan JS. 2013. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neuro Oncol. 15(Suppl 2):ii1–56.
   PubMed Web of Science ®Google Scholar
• Ostrom QT, Bauchet L, Davis FG, Deltour I, Fisher JL, Langer CE, Pekmezci M, Schwartzbaum JA, Turner MC, Walsh KM, et al. 2014. The epidemiology of glioma in adults: a “state of the science” review. Neuro Oncol. 16(7):896–913.
   PubMed Web of Science ®Google Scholar
• Patel SP, Kurzrock R. 2015. PD-L1 Expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther. 14(4):847–56.
   PubMed Web of Science ®Google Scholar
• Peng S, Wang R, Zhang X, Ma Y, Zhong L, Li K, Nishiyama A, Arai S, Yano S, Wang W, et al. 2019. EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression. Mol Cancer. 18(1):165.
   PubMed Web of Science ®Google Scholar
• Popovic D, Vucic D, Dikic I. 2014. Ubiquitination in disease pathogenesis and treatment. Nat Med. 20(11):1242–53.
   PubMed Web of Science ®Google Scholar
• Qin T, Zeng YD, Qin G, Xu F, Lu J-B, Fang W-F, Xue C, Zhan J-H, Zhang X-K, Zheng Q-F, et al. 2015. High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer. Oncotarget. 6(32):33972–81.
   PubMed Web of Science ®Google Scholar
• Shaid S, Brandts CH, Serve H, Dikic I. 2013. Ubiquitination and selective autophagy. Cell Death Differ. 20(1):21–30.
   PubMed Web of Science ®Google Scholar
• Shi SJ, Wang LJ, Wang GD, Guo Z-Y, Wei M, Meng Y-L, Yang A-G, Wen W-H. 2013. B7-H1 expression is associated with poor prognosis in colorectal carcinoma and regulates the proliferation and invasion of HCT116 colorectal cancer cells. PLoS One. 8(10):e76012.
   PubMed Web of Science ®Google Scholar
• Valles GJ, Bezsonova I, Woodgate R, Ashton NW. 2020. USP7 is a master regulator of genome stability. Front Cell Dev Biol. 8:717.
   PubMedGoogle Scholar
• Vidal S, El Motiam A, Seoane R, Preitakaite V, Bouzaher YH, Gómez-Medina S, San Martín C, Rodríguez D, Rejas MT, Baz-Martínez M, et al. 2019. Regulation of the Ebola virus VP24 protein by SUMO. J Virol. 94(1). doi:10.1128/JVI.01687-19.
   PubMedGoogle Scholar
• Wang X, Zhang Q, Wang Y, Zhuang H, Chen B. 2018. Clinical significance of ubiquitin specific protease 7 (USP7) in predicting prognosis of hepatocellular carcinoma and its functional mechanisms. Med Sci Monit. 24:1742–50.
   PubMedGoogle Scholar
• Wang X, Teng F, Kong L, et al. 2016. PD-L1 expression in human cancers and its association with clinical outcomes. Onco Targets Ther. 9:5023–39.
   PubMed Web of Science ®Google Scholar
• Wang Z, Kang W, Li O, Qi F, Wang J, You Y, He P, Suo Z, Zheng Y, Liu H-M, et al. 2021. Abrogation of USP7 is an alternative strategy to downregulate PD-L1 and sensitize gastric cancer cells to T cells killing. Acta Pharm Sin B. 11(3):694–707.
   PubMedGoogle Scholar
• Wildes TJ, Dyson KA, Francis C, Wummer B, Yang C, Yegorov O, Shin D, Grippin A, Dean BD, Abraham R, et al. 2020. Immune escape after adoptive T-cell therapy for malignant gliomas. Clin Cancer Res. 26(21):5689–700.
   PubMedGoogle Scholar
• Xu S, Tang L, Li X, Fan F, Liu Z. 2020. Immunotherapy for glioma: Current management and future application. Cancer Lett. 476:1–12.
   PubMed Web of Science ®Google Scholar
• Yi L, Cui Y, Xu Q, Jiang Y. 2016. Stabilization of LSD1 by deubiquitinating enzyme USP7 promotes glioblastoma cell tumorigenesis and metastasis through suppression of the p53 signaling pathway. Oncol Rep. 36(5):2935–45.
   PubMedGoogle Scholar
• Yin SS, Gao FH. 2020. Molecular mechanism of tumor cell immune escape mediated by CD24/Siglec-10. Front Immunol. 11:1324.
   PubMedGoogle Scholar
• Zhao L, Yu H, Yi S, Peng X, Su P, Xiao Z, Liu R, Tang A, Li X, Liu F, et al. 2016. The tumor suppressor miR-138-5p targets PD-L1 in colorectal cancer. Oncotarget. 7(29):45370–84.
   PubMedGoogle Scholar
• Zhou J, Wang J, Chen C, Yuan H, Wen X, Sun H. 2018. USP7: target validation and drug discovery for cancer therapy. Med Chem. 14(1):3–18.
   PubMedGoogle Scholar
• Zhu D, Xu R, Huang X, Tang Z, Tian Y, Zhang J, Zheng X. 2021. Deubiquitinating enzyme OTUB1 promotes cancer cell immunosuppression via preventing ER-associated degradation of immune checkpoint protein PD-L1. Cell Death Differ. 28(6):1773–89.
   PubMedGoogle Scholar